Clinical Trial Update: Safety and Immune Response to Two Doses of rDEN2/4delta30 Dengue Vaccine [Phase 1]

View source ↗

Summary

A Phase 1 trial assessed the safety and immune response to a two-dose regimen of the rDEN2/4delta30 dengue vaccine; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dengue Fever

Drugs mentioned

• rDEN2/4delta30 Dengue Vaccine

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Dengue Fever | Phase 1 | Status: COMPLETED